(NASDAQ: VRAX) Virax Biolabs Group's forecast annual revenue growth rate of 460,784.13% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 12,072.72%, and it is also forecast to beat the US market's average forecast revenue growth rate of 1,611.96%.
Virax Biolabs Group's revenue in 2026 is $2,986.On average, 3 Wall Street analysts forecast VRAX's revenue for 2026 to be $90,050,711, with the lowest VRAX revenue forecast at $86,517,258, and the highest VRAX revenue forecast at $92,700,801.
In 2027, VRAX is forecast to generate $26,697,203 in revenue, with the lowest revenue forecast at $25,650,253 and the highest revenue forecast at $27,482,414.